Randomized trial assesses hesperetin and isoliquiritigenin's effects on hepatic and renal complications in type 2 diabetic rats, suggesting potential as new therapies.
Key Points
This study aims to evaluate the effects of hesperetin and isoliquiritigenin on liver and kidney complications in type 2 diabetic rats.
Type 2 diabetes was induced in Wistar rats using a high-fat diet and streptozotocin injection.
Rats were treated orally with hesperetin (50 and 100 mg/kg), isoliquiritigenin (10 and 20 mg/kg), or empagliflozin (30 mg/kg) for 4 weeks.
Biochemical markers, blood glucose, and liver histology were assessed post-treatment.
Hesperetin and isoliquiritigenin significantly normalized biochemical markers and risk indexes in diabetic rats.
Treatment reduced blood glucose levels and improved beta-cell function, indicated by decreased HOMA-β levels.
Biochemical indicators of liver damage and oxidative stress were improved, alongside normalization of cytokine levels.